Table 1.
Clinical characteristics in 586 infection-naïve transplant recipients by serostatus following 3rd primary vaccine dose.
| Characteristics | No seroconversion | Seroconversion | p value | |
|---|---|---|---|---|
| N= 141 (%) | N= 445 (%) | |||
| Gender | Male | 93 (66.0) | 291 (65.4) | 0.90 |
| Female | 48 (34.0) | 154 (34.6) | ||
| Age at 1st vaccine | Years (Median) | 61 (51-68) | 60 (49-67) | 0.39 |
| Ethnicity | Caucasiana | 73 (51.8) | 221 (49.7) | 0.66 |
| Black | 13 (9.2) | 27 (6.1) | ||
| Indoasian | 38 (27.0) | 137 (30.8) | ||
| Other | 17 (12.1) | 60 (13.5) | ||
| Cause of ESKD | Polycystic kidney disease | 17 (12.1) | 52 (11.7) | 0.41 |
| Glomerulonephritisa | 41 (29.1) | 146 (32.8) | ||
| Diabetic nephropathy | 27 (19.1) | 67 (15.1) | ||
| Urological | 8 (5.7) | 43 (9.7) | ||
| Unknown | 30 (21.3) | 93 (20.9) | ||
| Other | 18 (12.8) | 44 (9.9) | ||
| Number of transplants received | 1 | 117 (83.0) | 395 (88.8) | 0.072 |
| ≥2 | 24 (17.0) | 50 (11.2) | ||
| 1st vaccine <1 year post- | No | 116 (82.3) | 418 (93.9) | <0.0001 |
| Transplant | Yes | 25 (17.7) | 27 (6.1) | |
| Type of transplant | Deceased Donor | 83 (58.9) | 240 (53.9) | 0.07 |
| Living Donora | 49 (34.8) | 193 (43.4) | ||
| Simultaneous Pancreas-Kidney | 9 (6.4) | 12 (2.7) | ||
| Induction agent | Alemtuzumaba | 76 (53.9) | 325 (73.0) | <0.0001 |
| IL2 receptor antagonist | 32 (22.7) | 41 (9.2) | ||
| None | 5 (3.5) | 16 (3.6) | ||
| Unknown | 28 (19.9) | 63 (14.2) | ||
| Immunosuppression type | CNI Monotherapya | 29 (20.6) | 244 (54.8) | <0.0001 |
| CNI/MMF (orAza) | 57 (40.4) | 99 (22.2) | ||
| CNI/MMF/Prednisolone | 42 (29.8) | 57 (12.8) | ||
| CNI/Prednisolone | 9 (6.4) | 42 (9.4) | ||
| MMF (or Aza)/Prednisolone | 1 (0.7) | 1 (0.2) | ||
| Other | 3 (2.1) | 2 (0.4) | ||
| Diabetes | No | 79 (56.0) | 307 (69.0) | 0.005 |
| Yes | 62 (44.0) | 138 (31.0) | ||
| Priming vaccine type | BNT162b22 | 61 (43.3) | 249 (56.0) | 0.0086 |
| ChAdOx12 | 80 (56.7) | 196 (44.0) | ||
| Time between 1st 2 vaccinations | Days (median) | 74 (63-78) | 75 (67-78) | 0.51 |
| Time between 2nd -3rd vaccinations | Days (median) | 167 (145-189) | 174 (156-189) | 0.033 |
| Time of serological test post-V3 | Days (median) | 24 (21-43) | 33 (21-53) | 0.007 |
a
Comparator. CNI (Calcineurin inhibitor); MMF (mycophenolate); Aza (Azathioprine).